It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study.
Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long-term ...